Eli Lilly & Corporation’s Revenue by Region (2014-2022)

You need Pro Plan to access KPI data.

Get 60% off on Pro

Discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

About

This statistic highlights Eli Lilly & Corporation’s Revenue by Region from 2014 onwards, split between Outside US and US, reported on an annual basis.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information

Subscribe to Pro or Enterprise plans to unlock this feature.

Contact the Analyst

Subscribe to Pro or Enterprise plans to unlock this feature.

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Eli Lilly & Corporation’s Revenue by Region from 2014 onwards, split between Outside US and US, reported on an annual basis.

The products offered by Eli Lilly & Corporation include Oncology products, Immunology products, Neuroscience products and Diabetes products.

Eli Lilly & Corporation’s Revenue by Region

The company sells most of its products worldwide. It adapts its marketing methods and product emphasis in various countries to meet local customer needs and comply with the local regulations. They sell their products in over 120 countries. The total revenue of the company has been rising continuously since 2014. It experienced a little drag down in 2018 as compared to 2017 but again it has been rising significantly since 2018. It grew from $21.49 million in 2018 to $22.32 million in 2019, increasing by 3.86%. The revenue further rose to $24.54 million in 2020, increasing by 9.94% from 2019.

The company’s revenue is further bifurcated into the following regions:

Revenue by Region 2018 2019 2020 Contribution in 2020
Outside US $9.10 $9.60 $10.31 42%
US $12.39 $12.72 $14.23 58%
Total $21.49 $22.32 $24.54 100%

(All figures are in millions, except percentages)

The U.S.

Majority of the company’s revenue comes from the US, accounting for 58%. The company promotes its major products in the U.S. through sales representatives. They also promote to healthcare providers through medical journals and online health care channels. In addition, they advertise certain products directly to consumers in the U.S. and they maintain websites with information about their major products. They supplement their employee sales force with contract sales organizations to leverage their resources and reach additional patients in need.

In the US, most of their products are distributed through wholesalers that serve pharmacies, physicians, other health care professionals, and hospitals. In 2020, 2019, and 2018, three wholesale distributors in the U.S.—McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc.—each accounted for 15 to 20 percent of their consolidated revenue. No other customer accounted for more than 10 percent of their consolidated revenue in any of these years.

Revenue from the US has been growing since 2018. It increased to $12.72 million in 2019 from $12.39 in 2018 by 3% and grew to $14.23 in 2020 at the rate of 12%. In the US, the revenue increase in 2020 was driven by increased volume primarily for Trulicity, bamlanivimab, and Taltz. excluding bamlanivimab revenue.

Outside the U.S.

Revenue from outside the U.S. account for 42% of the total revenue in 2020. Outside the U.S., they promote their products to healthcare providers primarily through sales representatives and online health care channels. While the products they market vary from country to country, diabetes products constitute the largest single group of their consolidated revenue. Distribution patterns for their products also vary from country to country. In most countries in which they operate, they maintain their own sales organizations, but in some smaller countries, they market their products through independent distributors.

Outside US revenue has also been growing since 2018. It increased to $9.60 million in 2019 from $9.10 million in 2018 which is a growth of 6% and then increased to $10.31 million in 2020 at the rate of 8%. The revenue increase in 2020 was driven by increased volume primarily for Tyvyt, Trulicity, Alimta, and Olumiant. The increase in volume and decrease in realized prices for Tyvyt and Alimta were driven primarily by their inclusion in government reimbursement programs in China.

About Eli Lilly & Corporation

Eli Lilly and Company was incorporated in 1901 in Indiana to succeed in the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. They work on developing, discovering, manufacturing and marketing pharmaceutical products. They operate in a single business segment—human pharmaceutical products. In March 2019, they completed the disposition of their ownership in Elanco Animal Health Incorporated (Elanco), an animal health business.

Their purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products they sell today were discovered or developed by their own scientists, and their long-term success depends on their ability to continually discover or acquire, develop, and commercialize innovative new medicines.

Did you like Eli Lilly & Corporation’s Revenue by Region statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount until Sunday

Pro

$19
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Billed annually, local taxes extra. 

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount on Annual plan

Pro

$49
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.